Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Target Recruit Count
- 21
- Registration Number
- NCT00607581
- Locations
- 🇮🇹
Amyloidosis Research and Treatment Center - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 84
- Registration Number
- NCT00603447
- Locations
- 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 45
- Registration Number
- NCT00602836
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 418
- Registration Number
- NCT00602459
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
🇺🇸Mount Carmel Health Center West, Columbus, Ohio, United States
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 306
- Registration Number
- NCT00602641
- Locations
- 🇺🇸
Illinois CancerCare-Havana, Havana, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸Marietta Memorial Hospital, Marietta, Ohio, United States
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT00580242
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00567229
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 35
- Registration Number
- NCT00564889
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma
- Conditions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT00555100
- Locations
- 🇯🇵
Keio University Hospital, Tokyo, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata, Japan
🇯🇵National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00553644
- Locations
- 🇺🇸
Kaiser Permanente-Irvine, Irvine, California, United States
🇺🇸Kaiser Permanente-Riverside, Riverside, California, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.